The National Cancer Institute's Technology Transfer Center (NCI TTC) recognizes the importance of converting basic science discoveries into public health benefits, and licenses research discoveries derived from its Intramural and Extramural laboratories. Since the government cannot engage in the development, manufacture, and sale of products, the TTC makes the discoveries of the NCI and nine other NIH Institutes and Centers available to organizations that can develop, manufacture, and distribute them to the public. In addition to discoveries from NCI laboratories, the NCI TTC also assists the following NIH Institutes in licensing:
- Center for Information Technology;
- Clinical Center;
- Eunice Kennedy Shriver National Institute on Child Health & Human Development;
- National Center for Complementary and Integrative Health;
- National Eye Institute;
- National Institute on Aging;
- National Institute on Drug Abuse;
- National Institute on Minority Health and Health Disparities; and
- National Library of Medicine;
The NCI TTC uses different licensing agreements that can be obtained from the Forms & Model Agreements page of the NIH Office of Technology Transfer site, with the exception of the Startup Exclusive License that is detailed elsewhere on this site.
License Agreements are legally binding and are subject to Federal, state, and local regulatory authorities. NIH licensees have the right to exclude others from making, using, importing, or selling the licensed invention within the field(s) of use identified within the license. The licensee can choose to license a technology using either an Exclusive License Agreement or a Non-exclusive License Agreement. The Exclusive License limits the use of the invention to a single group or entity in a particular field of use, while a Non-exclusive License allows the invention’s use by multiple entities within the same field of use. A license may cover one or more patented, or patent pending, inventions as well as unpatented biological materials or software code. The licensee will be required to pay licensing fees and make royalty payments, the frequency and amount of which are determined as part of the Licensing Application’s negotiation process. Payments and royalties are based in part on the type of license selected and other factors associated with the value of the licensed invention to the market place once commercialized.
The NCI TTC has developed several model License Agreements that serve as the baseline starting point for all license negotiations. A business development plan must be submitted as part of the license application process, and serves as the basis for establishing performance benchmarks that are included in the license agreement. Once a license is awarded, the NIH Office of Technology Transfer (OTT) and the NCI TTC work closely with licensees to monitor performance and to adjust benchmarks, when appropriate, to ensure successful commercial development of the invention. Licensees are also required to provide annual confidential reports on their “use of” or “commercialization efforts for” a licensed technology. These reports are kept confidential, to the extent permitted by law. The license is revocable under specific circumstances, such as (but not limited to): non-use of the patent, material breach of the terms, failure to comply with governing regulations or failure to satisfy public health needs.
The licensing process for NIH is described here.
Commercial Evaluation License Agreement
Short term (6-12 months);
Non-exclusive Patent License Agreement
(internal research use)
Biological Material License Agreement
Non-patented biological materials
Patented inventions and non-patented biological materials
Exclusive Patent License Agreement
NIH-patented inventions and non-patented biological materials
Start-up Exclusive Evaluation Option License Agreement
For Start-up companies: short-term and evaluation only
Start-up Exclusive Patent License Agreement
For Start-up companies
License Agreement Amendment
Amendment to executed license agreement